14585064|t|Torsade de pointes associated with the administration of intravenous haloperidol:a review of the literature and practical guidelines for use.
14585064|a|Haloperidol is the most commonly used medication for the treatment of delirium and psychosis in the critically ill patient. Whilst generally considered to be safe, haloperidol has been associated with a number of important cardiovascular side effects. The major toxicities include hypotension, cardiac arrhythmias and prolongation of the corrected QT (QTc) interval. In particular, torsade de pointes, a polymorphic ventricular tachyarrhythmia, has been associated with both intravenous and oral haloperidol administration. The management of torsade de pointes consists of discontinuation of the possible offending agent(s), correction of electrolyte abnormalities, administration of magnesium sulfate and, if necessary, overdrive pacing. Although clinicians should be aware of this potentially lethal complication of intravenous haloperidol therapy, it should not deter clinicians from using intravenous haloperidol to treat acute agitation in the critically ill patient with a normal QTc.
14585064	0	18	Torsade de pointes	Disease	MESH:D016171
14585064	69	80	haloperidol	Chemical	MESH:D006220
14585064	142	153	Haloperidol	Chemical	MESH:D006220
14585064	212	220	delirium	Disease	MESH:D003693
14585064	225	234	psychosis	Disease	MESH:D011618
14585064	242	256	critically ill	Disease	MESH:D016638
14585064	257	264	patient	Species	9606
14585064	306	317	haloperidol	Chemical	MESH:D006220
14585064	365	392	cardiovascular side effects	Disease	MESH:D064420
14585064	404	414	toxicities	Disease	MESH:D064420
14585064	423	434	hypotension	Disease	MESH:D007022
14585064	436	455	cardiac arrhythmias	Disease	MESH:D001145
14585064	460	507	prolongation of the corrected QT (QTc) interval	Disease	MESH:D008133
14585064	524	542	torsade de pointes	Disease	MESH:D016171
14585064	558	585	ventricular tachyarrhythmia	Disease	MESH:D014693
14585064	638	649	haloperidol	Chemical	MESH:D006220
14585064	684	702	torsade de pointes	Disease	MESH:D016171
14585064	781	806	electrolyte abnormalities	Disease	MESH:D014883
14585064	826	843	magnesium sulfate	Chemical	MESH:D008278
14585064	972	983	haloperidol	Chemical	MESH:D006220
14585064	1047	1058	haloperidol	Chemical	MESH:D006220
14585064	1074	1083	agitation	Disease	MESH:D011595
14585064	1091	1105	critically ill	Disease	MESH:D016638
14585064	1106	1113	patient	Species	9606
14585064	Positive_Correlation	MESH:D006220	MESH:D014693
14585064	Positive_Correlation	MESH:D006220	MESH:D016171
14585064	Positive_Correlation	MESH:D006220	MESH:D001145
14585064	Positive_Correlation	MESH:D006220	MESH:D008133
14585064	Negative_Correlation	MESH:D006220	MESH:D011618
14585064	Positive_Correlation	MESH:D006220	MESH:D007022
14585064	Negative_Correlation	MESH:D006220	MESH:D003693
14585064	Negative_Correlation	MESH:D006220	MESH:D011595
14585064	Negative_Correlation	MESH:D008278	MESH:D016171
14585064	Negative_Correlation	MESH:D006220	MESH:D016638

